Crux Wealth Advisors Has $1.31 Million Holdings in Medtronic PLC $MDT

Crux Wealth Advisors lifted its position in shares of Medtronic PLC (NYSE:MDT) by 5.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,058 shares of the medical technology company’s stock after purchasing an additional 791 shares during the quarter. Crux Wealth Advisors’ holdings in Medtronic were worth $1,313,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MDT. 1248 Management LLC bought a new position in shares of Medtronic in the first quarter valued at $26,000. Columbia River Financial Group LLC bought a new stake in shares of Medtronic during the first quarter worth about $28,000. Twin Tree Management LP acquired a new stake in shares of Medtronic in the 1st quarter worth about $29,000. Activest Wealth Management lifted its position in Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 322 shares in the last quarter. Finally, Hughes Financial Services LLC bought a new position in Medtronic in the 1st quarter valued at about $32,000. 82.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on MDT shares. Morgan Stanley reissued an “overweight” rating and set a $107.00 price objective (up from $98.00) on shares of Medtronic in a report on Tuesday, July 15th. UBS Group lifted their target price on Medtronic from $94.00 to $95.00 and gave the company a “neutral” rating in a research report on Wednesday, August 20th. Evercore ISI increased their price target on Medtronic from $103.00 to $106.00 and gave the company an “outperform” rating in a research report on Tuesday, July 8th. William Blair raised shares of Medtronic to a “hold” rating in a report on Friday, July 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Medtronic in a research note on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Medtronic currently has an average rating of “Moderate Buy” and a consensus price target of $102.82.

Medtronic Stock Up 0.6%

MDT stock opened at $95.62 on Friday. The stock has a market cap of $122.65 billion, a P/E ratio of 26.34, a P/E/G ratio of 2.52 and a beta of 0.78. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The stock’s fifty day simple moving average is $94.07 and its two-hundred day simple moving average is $88.98. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $99.37.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.03. The company had revenue of $8.58 billion for the quarter, compared to analysts’ expectations of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 17th. Stockholders of record on Friday, September 26th were paid a dividend of $0.71 per share. The ex-dividend date was Friday, September 26th. This represents a $2.84 annualized dividend and a dividend yield of 3.0%. Medtronic’s dividend payout ratio (DPR) is presently 78.24%.

Insider Buying and Selling

In other news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This represents a 19.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William R. Jellison acquired 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The stock was purchased at an average cost of $92.37 per share, with a total value of $230,925.00. Following the acquisition, the director owned 5,000 shares in the company, valued at $461,850. The trade was a 100.00% increase in their position. The disclosure for this purchase can be found here. Insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.